Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) Net Income towards Common Stockholders: 2010-2023

Historic Net Income towards Common Stockholders for SELLAS Life Sciences Group (SLS) over the last 9 years, with Dec 2023 value amounting to -$37.9 million.

  • SELLAS Life Sciences Group's Net Income towards Common Stockholders rose 13.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 9.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 8.31% up from last year.
  • As of FY2023, SELLAS Life Sciences Group's Net Income towards Common Stockholders stood at -$37.9 million, which was up 8.31% from -$41.3 million recorded in FY2022.
  • Over the past 5 years, SELLAS Life Sciences Group's Net Income towards Common Stockholders peaked at -$16.8 million during FY2020, and registered a low of -$41.3 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$33.3 million, with a median of -$37.9 million in 2023.
  • In the last 5 years, SELLAS Life Sciences Group's Net Income towards Common Stockholders skyrocketed by 39.77% in 2020 and then crashed by 99.53% in 2022.
  • Over the past 5 years, SELLAS Life Sciences Group's Net Income towards Common Stockholders (Yearly) stood at -$28.0 million in 2019, then spiked by 39.77% to -$16.8 million in 2020, then decreased by 22.95% to -$20.7 million in 2021, then slumped by 99.53% to -$41.3 million in 2022, then climbed by 8.31% to -$37.9 million in 2023.